Preoperative RT with pembrolizumab showed high pathologic complete response rates and notable three-year event-free survival in TNBC and HR+/HER2- patients with breast cancer. PD-L1 expression and ...
Radiation therapy combined with Keytruda increased T cell infiltration in HR+ and HER2-negative breast cancer, enhancing immune response. High-dose radiation with Keytruda led to increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback